Unassociated Document
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
___________
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): December 8, 2008
 
BODISEN BIOTECH, INC.
(Exact Name of Registrant as Specified in Charter)
 
 
Delaware
001-32616
98-0381367
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
 
Room 2001, FanMei Building
No. 1 Naguan Zhengjie
Xi’an Shaanxi  710068
Peoples Republic of China
(Address of Principal Executive Offices) (Zip Code)
 
Registrant’s telephone number, including area code: 86-29-87074957
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 1.01.  Decision and Order received by the United States Federal Court
 
N/A

Item 2.01 Other Events

 
(a)
On December 8, 2008 the Company issued a press release announcing the results of the Town Hall Meeting held on December 2, 2008 in Alaer City, Xinjiang, China.  A copy of the press release is attached hereto as Exhibit 2.01 and is incorporated herein by reference.
 
 
Exhibit No.
Description
     
 
2.01
Press release dated December 8, 2008 furnished herewith.

 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
  BODISEN BIOTECH, INC.  
       
Date: December 8, 2008
By:
/s/ Bo Chen  
   
Name: Bo Chen
Title: Chairman, Chief Executive Officer and President
  
       
       
 
 
 
 
 
Exhibit Index
 
 
Exhibit No.
Description
     
 
2.01
Press release dated December 8, 2008 furnished herewith.